FDA

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

News

Last places on FDA START rare disease programme filled

The last three slots for projects that will be included in the FDA’s new programme to accelerate the development of therapies for rare diseases have been taken by Moderna,

News

Geron finally brings a drug to market as FDA clears Rytelo

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.

News

First rare disease therapies chosen for FDA START programme

An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen

News

FDA panel votes against Lykos’ pioneer psychedelic therapy

FDA independent advisors have comprehensively voted against the use of Lykos Therapeutics’ therapy for post-traumatic stress disorder (PTSD) based on MDMA, also known as e

News

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

Last places on FDA START rare disease programme filled

Geron finally brings a drug to market as FDA clears Rytelo

First rare disease therapies chosen for FDA START programme

FDA panel votes against Lykos’ pioneer psychedelic therapy

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks